From: JEnglish@technip.com
Sent: Friday, June 04, 2004 4:01 PM
To: HENIGA@cder.fda.gov
Cc: fdadockets@oc.fda.gov; SaOstrove@technip.com
Subject: Re: Part 11 meeting - Docket number 2004N-0133 - initial
transmittal





Anne:

Please find attached the text of my presentation.  I am sending it now as a
precaution against some difficulty with the powerpoint.
This is the requested presentation as per you e-mail and confirmation
letter dated 25 MAY 2004.

(See attached file: JEnglish_FDAPart11_Docket2004N-1033.pdf)

Please advise if there are any problems opening it, or with the choice of
format.  As a precaution, since I will be away form e-mail until Monday
evening, you should cc: Dr Steve Ostrove with any issues.  (He is included
on this email as well.  His internet address is SAOstrove@technip.com)

Best regards,

John English, Principal Validation Consultant
TECHNIP BioPharm Inc.
106 Allen Road, Suite 300 - Rm 3261
Liberty Corner, NJ 07938 - USA
Tel:  +1.908.604.7552
Fax: +1.908.604.7501
Cell:+1.973.727.5679
E-mail:  jenglish@technip.com
Technip BioPharm (In Progress):  http://www.technipbiopharm.com
Technip Life Sciences Page:
http://www.technip.com/english/experience/life.htm